Latest Conference Articles

Vadastuximab Talirine Yields Rapid and Deep Remissions in Early Study of Patients With AML

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

Dr. Tam on Trials Investigating BGB-3111 in CLL and Waldenstrom's Macroglobulinemia

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

TKI Cessation Strategies Emerging for CML

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

Impressive Brentuximab Vedotin Data May Change Practice in CTCL

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Acalabrutinib Monotherapy Effective for Richter Transformation

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Nivolumab/Ibrutinib Combo Shows Promise for Richter Transformation

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Dr. Ahluwalia on Using Precision Medicine to Treat Brain Metastases

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

Durvalumab Shows Durable Activity in Recurrent GBM

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

AG-120 Shows Early Efficacy in IDH1-Mutant Glioma

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.

Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Dr. Fine on Therapeutic Metabolic Targets in Brain Cancer

Optune Survival Benefit in GBM Sustained With Long-Term Data

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

Checkpoint Inhibitors Show Promise in Glioblastoma

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Toca 511 Shows Promise in High-Grade Glioma

The gene for an anticancer drug was successfully transduced in high-grade gliomas, which resulted in an improvement in overall survival, according to data from a phase I trial of Toca 511.

Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC

​Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.